Hengrui Pharma targets obesity drug launch after test success
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials Key Takeaways: Participants receiving…
BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
Sihuan Pharma’s Botox Beauty Bid Suffers Covid Wrinkle
The cardiovascular and cancer drug maker’s recent shift to the medical beauty business was doing well at first, but struggled last yearKey Takeaways:Sihuan Pharmaceutical’s recent move into the medical beauty…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
1276.HK 600276.SHG
- RNA drug developer Ribo Life targets fresh funding channel
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
